Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

AVTX holding history

Avalo Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AVTX overviewAll 13F holders of AVTXFull Q2 2026 holdings

Shares (Q2 2026)
1,209,059
Value
$22.3M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of AVTX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,209,059$22.3M<0.1%+67,079+5.9%AddedHolders
Q1 20261,141,980$17.0M<0.1%+664,164+139.0%AddedHolders
Q4 2025477,816$8.68M<0.1%+432,608+956.9%AddedHolders
Q3 202545,208$574.6K<0.1%−38,516−46.0%ReducedHolders
Q2 202583,724$417.8K<0.1%−15,227−15.4%ReducedHolders
Q1 202598,951$792.6K<0.1%+432+0.4%AddedHolders
Q4 202498,519$732.0K<0.1%+92,385+1,506.1%AddedHolders
Q3 20246,134$58.3K<0.1%+2,551+71.2%AddedHolders
Q2 20243,583$44.7K<0.1%−4,130−53.5%ReducedHolders
Q1 20247,713$167.8K<0.1%+7,711+385,550.0%AddedHolders
Q4 20232$18<0.1%−110−98.2%ReducedHolders
Q3 2023112$14<0.1%−1,807−94.2%ReducedHolders
Q2 20231,919$680<0.1%−431−18.3%ReducedHolders
Q1 20232,350$4.11K<0.1%−3,827−62.0%ReducedHolders
Q4 20226,177$31.1K<0.1%−583−8.6%ReducedHolders
Q3 20226,760$22.0K<0.1%+6,050+851.4%AddedConverted for a 1-for-12 splitHolders
Q2 20228,526$4.00K<0.1%−13,864−61.9%ReducedHolders
Q1 202222,390$15.0K<0.1%+4,596+25.8%AddedHolders
Q4 202117,794$30.0K<0.1%+17,745+36,214.3%AddedHolders
Q3 202149$00.0%−89−64.5%ReducedHolders
Q2 2021138$00.0%−13,395−99.0%ReducedHolders
Q1 202113,533$40.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.